SRR934980
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INFLAMMATORY_RESPONSE+0.417
- TNFA_SIGNALING_VIA_NFKB+0.417
- ALLOGRAFT_REJECTION+0.397
- INTERFERON_GAMMA_RESPONSE+0.386
- APOPTOSIS+0.373
- KRAS_SIGNALING_UP+0.365
- COMPLEMENT+0.353
- IL2_STAT5_SIGNALING+0.292
- TGF_BETA_SIGNALING+0.264
Top 10 suppressed
- MYC_TARGETS_V2-0.419
- DNA_REPAIR-0.292
- OXIDATIVE_PHOSPHORYLATION-0.249
- MYC_TARGETS_V1-0.155
- UNFOLDED_PROTEIN_RESPONSE-0.144
- HEDGEHOG_SIGNALING-0.068
- WNT_BETA_CATENIN_SIGNALING-0.059
- SPERMATOGENESIS-0.057
- MYOGENESIS-0.021
- GLYCOLYSIS-0.011
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.875 |
| 2 | SRR5088852 | — | — | 0.872 |
| 3 | DRR168605 | — | — | 0.867 |
| 4 | TCGA-AN-A0XW-01A-11R-A109-07 | — | C | 0.867 |
| 5 | 957a7228-3558-48fd-81d9-13f951e0b597 | — | — | 0.861 |
| 6 | MNG1172 | — | — | 0.861 |
| 7 | MDT-AP-2990 | Med | Medulloblastoma | 0.855 |
| 8 | BS_0SCXXM6N | low-grade glioma | — | 0.849 |
| 9 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.848 |
| 10 | BS_593HEWBF | Ganglioglioma | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.417 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.417 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.397 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.386 | Idelalisib | — uncovered |
| APOPTOSIS | 0.373 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.365 | Inavolisib | — uncovered |
| COMPLEMENT | 0.353 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.292 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.264 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.252 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.249 | Cobimetinib | — uncovered |
| COAGULATION | 0.241 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.234 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.233 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.229 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.228 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.208 | Inavolisib | — uncovered |